Fixed combination of oxycodone with naloxone: A new way to prevent and treat opioid-induced constipation

Advances in Therapy

Volumn 27, Issue 9, 2010, Pages 581-590

  Mueller Lissner, Stefan ^a  

^a Park Klinik Weissensee   (Germany)

Author keywords

constipation; naloxone; opioids; oxycodone

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; OPIATE ANTAGONIST; OXYCODONE; PLACEBO;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACETYLCHOLINE RELEASE; ANALGESIC ACTIVITY; COLONOSCOPY; CONSTIPATION; CONVALESCENCE; DIARRHEA; DIGITAL RECTAL EXAMINATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DYSPEPSIA; GASTROINTESTINAL MOTILITY; GLUCURONIDATION; HUMAN; HYSTERECTOMY; IDIOPATHIC DISEASE; ILEUS; INTESTINE FUNCTION; INTESTINE RESECTION; LIFESTYLE; NAUSEA; OPIOID INDUCE CONSTIPATION; OPIOID INDUCED CONSTIPATION; PAIN; PHYSICAL ACTIVITY; REVIEW; VOMITING;

ANALGESICS, OPIOID; CONSTIPATION; DRUG COMBINATIONS; HUMANS; LAXATIVES; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; OXYCODONE; PAIN; TREATMENT OUTCOME;

EID: 77956229576     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0057-y     Document Type: Review

References (58)

1. H.U. De Schepper F. Cremonini M.I. Park M. Camilleri 2004 Opioids and the gut: pharmacology and current clinical experience Neurogastroenterol Motil 16 383 394 10.1111/j.1365-2982.2004.00513.x 15305992
2. G.W. Pasternak 1993 Pharmacological mechanisms of opioid analgesics Clin Neuropharmacol 16 1 18 10.1097/00002826-199302000-00001 8093680
3. D.B. Murphy J.A. Sutton L.F. Prescott M.B. Murphy 1997 Opioid induced delay in gastric emptying: a peripheral mechanism in humans Anesthesiology 87 765 770 10.1097/00000542-199710000-00008 9357876
4. Smith KJ, Hopp M, Mundin G, Bond S, Connor A. Oxycodone/Naloxone prolonged release tablets reduce oxycodone-induced prolongation of gastrointestinal transit. 5th World Congress of the World Institute of Pain, New York, NY, USA; March 13-16, 2009.
5. P.N. Kaufman B. Krevsky L.S. Malmud 1988 Role of opiate receptors in the regulation of colonic transit Gastroenterology 94 1351 1356 2834257
6. J. Shook J.P. Pelton V.J. Hruby T.F. Burks 1987 Peptide opioid antagonist separates peripheral and central opioid antitransit effects J Pharmacol Exp Ther 243 492 500 2824748
7. G. Longstreth W. Thompson W. Chey L. Houghton F. Mearin R. Spiller 2006 Functional bowel disorders Gastroenterology 130 1480 1491 10.1053/j.gastro.2005. 11.061 16678561
8. T.J. Bell S.J. Panchal C. Miaskowski S.C. Bolge T. Milanova R. Williamson 2009 The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1) Pain Med 10 35 42 10.1111/j.1526-4637.2008.00495.x 18721170
9. R.A. Moore H.J. McQuay 2005 Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids Arthritis Res Ther 7 R1046 1051 10.1186/ar1782 16207320
10. J.A.H. Puxty R.A. Fox 1986 Golytely: a new approach to faecal impaction in old age Age Ageing 15 182 184 10.1093/ageing/15.3.182 3739857
11. S.F. Cook L. Lanza X. Zhou 2008 Gastrointestinal side effects in chronic opioid users: results from a population-based survey Aliment Pharmacol Ther 27 1224 1232 10.1111/j.1365-2036.2008.03689.x 18363893
12. L. Allan U. Richarz K. Simpson R. Slappendel 2005 Transdermal fentanyl versus sustained release oral morphine in strong-opioid naIve patients with chronic low back pain Spine 30 2484 2490 10.1097/01.brs.0000186860.23078.a8 16284584
13. E.C. Davies C.F. Green D.R. Mottram M. Pirmohamed 2008 The use of opioids and laxatives, and incidence of constipation, in patients requiring neck-of-femur (NOF) surgery: a pilot study J Clin Pharm Ther 33 561 566 10.1111/j.1365-2710.2008.00949.x 18834372
14. J. Droney J. Ross S. Gretton K. Welsh H. Sato J. Riley 2008 Constipation in cancer patients on morphine Support Care Cancer 16 453 459 10.1007/s00520-007-0373-1 18197439
15. M. Hale I.C. Tudor S. Khanna J. Thipphawong 2007 Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis Clin Ther 29 874 888 10.1016/j.clinthera.2007.05.016 17697906
16. M.E. Hale H. Ahdieh T. Ma R. Rauck Oxymorphone ER Study Group 1 2007 Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study J Pain 8 175 184 10.1016/j.jpain.2006.09.011 17145204
17. H.G. Kress D. Von der Laage K.H. Hoerauf 2008 A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain J Pain Symptom Manage 36 268 779 10.1016/j.jpainsymman.2007.10.023 18538974
18. C.A. Marco M.C. Plewa N. Buderer C. Black A. Roberts 2005 Comparison of oxycodone and hydrocodone for the treatment of acute pain associated with fractures: a double-blind, randomized, controlled trial Acad Emerg Med 12 282 288 10.1111/j.1553-2712.2005.tb01941.x 15805317
19. A.K. Matsumoto N. Babul H. Ahdieh 2005 Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial Pain Med 6 357 366 10.1111/j.1526-4637.2005. 00057.x 16266356
20. R.K. Portenoy J.T. Farrar M.M. Backonja 2007 Longterm use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study Clin J Pain 23 287 299 10.1097/AJP.0b013e31802b582f 17449988
21. P.S. Staats J. Markowitz J. Schein 2004 Incidence of constipation associated with longacting opioid therapy: A comparative study South Med Journal 97 129 134 10.1097/01.SMJ.0000109215.54052.D8
22. A.K. Tuteja J. Biskupiak G.J. Stoddard A.G. Lipman 2010 Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain Neurogastroenterol Motil 22 424 430 10.1111/j.1365-2982.2009.01458.x 20100280
23. S.M. Weinstein M. Shi B.J. Buckley M.A. Kwarcinski 2006 Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain Clin Ther 28 86 98 10.1016/j.clinthera.2006.01.010 16490582
24. S. Wirz M. Wittmann M. Schenk 2009 Gastrointestinal symptoms under opioid therapy: A prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine Eur J Pain 13 737 743 10.1016/j.ejpain.2008.09.005 18977159
25. S.J. Panchal P. Müller-Schwefe J.I. Wurzelmann 2007 Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden Int J Clin Pract 61 1181 1187 10.1111/j.1742-1241.2007.01415.x 17488292
26. M. Pappagallo 2001 Incidence, prevalence, and management of opioid bowel dysfunction Am J Surg 1825ASuppl. 11S 18S 10.1016/S0002-9610(01)00782-6
27. M. L. Bouvy H. Buurma T.C.G. Egberts 2002 Laxative prescribing in relation to opioid use and the influence of pharmacy-based intervention J Clin Pharm Ther 27 107 110 10.1046/j.1365-2710.2002.00385.x 11975694
28. J. Thomas 2008 Opioid-induced bowel dysfunction J Pain Symptom Manage 35 103 113 10.1016/j.jpainsymman.2007.01.017 17981003
29. M.D. Freedman H.J. Schwartz R. Roby S. Fleisher 1997 Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial J Clin Pharmacol 37 904 907 9505981
30. P.H. Hawley J.J. Byeon 2008 A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer J Pall Med 11 575 581 10.1089/jpm.2007.0178
31. D.E. Moulin A. Rykx R. Kerstens L. Vandenplassche 2008 Randomized double-blind placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor) in patients with opioid-induced constipation Gastroenterol 134 A92
32. O. Olsen T. Håkansson J.I. Forrest 1985 Bisocadyl in the treatment of postoperative intestinal atony Ugeskr Laeger 147 3070 3071 3907074
33. E. McNicol D.B. Boyce R. Schumann D. Carr 2008 Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials Pain Med 9 634 659 10.1111/j.1526-4637.2007.00335.x 18828197
34. B.H. Chamberlain K. Cross J.L. Winston 2009 Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness J Pain Symptom Manage 38 683 690 10.1016/j.jpainsymman.2009.02.234 19713070
35. N. Slatkin J.T. Thomas A.G. Lipman 2009 Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients J Support Oncol 7 39 46 19278178
36. J. Thomas S. Karver G.A. Cooney 2008 Methylnaltrexone for opioid-induced constipation in advanced illness N Engl J Med 358 2332 2343 10.1056/ NEJMoa0707377 18509120
37. M.W. Büchler C.M. Seiler J.R. Monson 2008 Clinical trial: alvimopan for the management of postoperative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study Aliment Pharmacol Ther 28 312 325 10.1111/j.1365-2036.2008.03696. x 19086236
38. K. Ludwig W.E. Enker C.P. Delaney 2008 Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway Arch Surg 143 1098 1105 10.1001/archsurg.143.11.1098 19015469
39. B.G. Wolff F. Michelassi T.M. Gerkin 2004 Alvimopan, a novel, peripherally acting opioid antagonist Ann Surg 240 728 735 15383800
40. K.P. Leow M.T. Smith B. Williams T. Cramond 1992 Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer Clin Pharmacol Ther 52 487 495 1424423
41. R.F. Reder B. Oshlack J.B. Miotto D.D. Benziger R.F. Kaiko 1996 Steady-state bioavailability of controlled-release oxycodone in normal subjects Clin Ther 18 95 105 10.1016/S0149-2918(96)80182-2 8851456
42. R.D. Colucci R.E. Swanton G.B. Thomas R.F. Kaiko 2001 Relative variability in bioavailability of oral controlled-release formulations of oxycodone and morphine Am J Ther 8 231 236 10.1097/00045391-200107000-00004 11441321
43. P. Mucci-LoRusso B.S. Berman P.T. Silberstein 1998 Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, paraIlel-group study Eur J Pain 2 233 249 10.1016/S1090-3801(98)90020-9
44. J. Fishman H. Roffwarg L. Hellman 1973 Disposition of naloxone-7,8-3H in normal and narcotic dependent men J Pharmacol Exp Ther 187 575 580 4588968
45. S.H. Weinstein M. Pfeffer J.M. Schor 1973 Metabolism and pharmacokinetics of naloxone Adv Biochem Psychopharmacol 8 525 535 4794980
46. H. Albeck S. Woodfield M.J. Kreek 1989 Quantitative and pharmacokinetic analysis of naloxone in plasma using high-performance liquid chromatography with electrochemical detection and solid-phase extraction J Chromatogr 488 435 445 10.1016/S0378-4347(00)82967-9 2745633
47. G. Basilisco G. Camboni A. Bozzani M. Paravicini P.A. Bianchi 1987 Oral naloxone antagonizes loperamide-induced delay of orocecal transit Dig Dis Sci 32 829 832 10.1007/BF01296704 3608730
48. N.D. Hawkes C. Richardson B.K. Evans J. Rhodes S.J. Lewis G.A. Thomas 2001 Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine Aliment Pharmacol Ther 15 625 630 10.1046/j.1365-2036.2001.00970.x 11328255
49. P. Holzer 2004 Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans Neurosci Lett 361 192 195 10.1016/j.neulet.2003.12.004 15135926
50. M.J. Kreek R.A. Schaefer E.F. Hahn J. Fishman 1983 Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation Lancet i 261 262 10.1016/S0140-6736(83)91684-7
51. N.P. Sykes 1996 An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer Palliat Med 10 135 144 10.1177/026921639601000208 8800821
52. M. Liu E. Wittbrodt 2002 Low-dose oral naloxone reverses opioid-induced constipation and analgesia J Pain Symptom Manage 23 48 53 10.1016/S0885-3924(01) 00369-4 11779668
53. K. Smith M. Hopp G. Mundin 2008 Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers Clin Ther 30 2051 2068 10.1016/j.clinthera.2008.11.008 19108793
54. W. Meissner P. Leyendecker S. Mueller-Lissner 2009 A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation Eur J Pain 13 56 64 10.1016/j.ejpain. 2008.06.012 18762438
55. A.M. Rentz R. Yu S.A. Müller-Lissner P. Leyendecker 2009 Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation J Med Econ 12 371 383 10.3111/13696990903430481 19912069
56. K. Simpson P. Leyendecker M. Hopp 2008 Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate to severe noncancer pain Curr Med Res Opin 24 3503 3512 10.1185/03007990802584454 19032132
57. O. Löwenstein P. Leyendecker M. Hopp 2009 Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial Expert Opin Pharmacother 10 531 543 10.1517/14656560902796798 19243306
58. Ballantyne JC, Carwood C. Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database Syst Rev. 2005;(2):CD005178.